0611/26SCR019-18/R6RGB
Media Highlights
From the 2026 ASCO® Annual Meeting
6
Continued ➔
Meredith Pelster, MD, MSCI
SCRI
Media Outlet Date Article / Coverage
BioSpace 5/26/26 All Eyes on Revolution, Bispecific Antibodies and
More at ASCO26
BioSpace 6/1/26 ASCO: Biopharma Has Pancreatic Cancer 'Surrounded' As
Immuneering's Drug Adds 9 Quality Months
BioSpace 6/1/26 ASCO: Revolution Poised to Capture Ras Space As Pancreatic
Cancer Dataset 'Derisks' Approval
Patient Daily 6/2/26 Immuneering's Pancreatic Cancer Drug Shows Extended
Survival in Phase 2a Trial
Patient Daily 5/26/26 ASCO 2026 to Spotlight Revolution Medicines and Bispecific
Antibody Advances
Sarah Premji, MD
SCRI
Media Outlet Date Article / Coverage
DocWire News 5/20/26 HR+ Breast Cancer at ASCO 2026: Emerging Data to Watch
DocWire News 5/26/26 ASCO 2026 Preview: Breakthroughs in TNBC and HER2+
Breast Cancer
DocWire News 6/10/26 Biparatopic HER2 Targeting in Action: Anbenitamab's
Phase 3 Breakthrough
